You can buy or sell XENE and other stocks, options, ETFs, and crypto commission-free!
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Read More Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Burnaby, British Columbia
52 Week High
52 Week Low
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2019 and provided a corporate update. Dr. Simon Pimstone, Xenon's Chief Executive Officer, said, "We contin...
Yahoo FinanceApr 30
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
BURNABY, British Columbia, April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, May 7, 2019. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please di...
Expected Aug 6, After Hours